Patients
Following Institutional Review Board approval, we performed a
retrospective analysis of all patients
diagnosed with recurrent uLMS who
presented to our institution from January 1, 2001 to January 1, 2020.
All patients had previously undergone either total hysterectomy or
radical hysterectomy or myomectomy at our center or an outside
institution and diagnosed with uLMS after primary surgery which
confirmed by an experienced gynecologic pathologist in our hospital.
Only patients with first recurrent uLMS were included. Patients received
treatment in the Department of Gynecological Oncology of Cancer
Hospital, Chinese Academy of Medical Sciences, National Cancer Center.
The cohort was divided into two subgroups according to whether receive
secondary cytoreductive surgery (SCS) for recurrent uLMS: the SCS
subgroup, and non-SCS subgroup. The patients’ full medical records were
included in this study. Clinical and pathologic variables, treatment
modalities, and outcomes were assessed. Stage was retrospectively
assigned using the International Federation of Gynecology and Obstetrics
(FIGO) 2008 staging system for uterine sarcomas.